| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.25 | 1e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.24 | 2e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.28 | 4e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.17 | 7e-06 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-05 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.24 | 4e-05 |